Lacromid

Bezafibrate, the active ingredient in Lacromid, is a fibrate presented as a tablet for oral use. It treats elevated blood lipids, including high cholesterol and triglycerides, in adults with hyperlipidemia, hypertriglyceridemia, or mixed dyslipidemia, helping to reduce cardiovascular risk. As a member of the lipid‑modifying fibrate class, it activates peroxisome proliferator‑activated receptor alpha (PPARα) to enhance fatty‑acid oxidation.

GNH USA supplies Lacromid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable delivery across Europe, Asia and Africa.

Bezafibrate is used to manage disorders of lipid metabolism. - Hyperlipidemia: reduces total cholesterol and low‑density lipoprotein (LDL) levels, contributing to decreased atherosclerotic risk. - Hypertriglyceridemia: lowers elevated triglyceride concentrations, helping to prevent pancreatitis and related complications. - Mixed dyslipidemia: improves the overall lipid profile by decreasing triglycerides and LDL cholesterol while modestly raising high‑density lipoprotein (HDL) levels. - Cardiovascular risk reduction: when combined with diet and lifestyle measures, it may contribute to lower incidence of cardiovascular events.

Bezafibrate may be associated with a range of adverse reactions, varying from mild to serious. Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia. - Headache: mild to moderate intensity. - Dizziness or light‑headedness. - Elevated liver enzymes: transient increase in ALT/AST. - Muscle pain or weakness: mild myalgia. - Skin rash: mild erythema or itching. Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with risk of renal failure. - Hepatic failure: marked elevation of liver enzymes or jaundice. - Gallstone formation: biliary colic or cholecystitis. - Pancreatitis: acute inflammation of the pancreas. - Severe hypersensitivity: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Blood dyscrasias: agranulocytosis or thrombocytopenia.

Before initiating Bezafibrate therapy, clinicians should consider several precautionary measures to ensure patient safety. - Liver function monitoring: assess baseline ALT/AST and repeat periodically. - Renal function assessment: evaluate creatinine clearance, especially in elderly patients. - Gallbladder disease evaluation: avoid use in patients with active gallstones or biliary obstruction. - Muscle toxicity vigilance: monitor for unexplained muscle pain, especially if combined with statins. - Drug interaction review: check concomitant use of cytochrome P450 inhibitors or other fibrates. - Store below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Bezafibrate can interact with other medicines, altering its efficacy or safety profile. Major Interactions (Avoid): - Cyclosporine: increased risk of myopathy and renal toxicity. - Gemfibrozil: additive muscle toxicity leading to rhabdomyolysis. - High‑dose statins (e.g., simvastatin >20 mg): heightened risk of severe myopathy. - Warfarin: potentiation of anticoagulant effect, requiring INR monitoring. - Cholesterol‑binding resins (e.g., cholestyramine): reduced absorption of Bezafibrate. Moderate Interactions (Monitor Closely): - Oral hypoglycemic agents: potential enhancement of hypoglycemia. - NSAIDs: may increase renal adverse effects. - ACE inhibitors or ARBs: monitor renal function and electrolytes. - Thyroid hormone replacement: possible alteration of thyroid hormone levels. - Other lipid‑lowering agents: assess cumulative lipid effects and liver enzymes.